NCT06131801View on ClinicalTrials.gov

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Hematologic MalignancyLeukemiaLymphomaAcute Lymphocytic LeukemiaALLAcute Myelogenous LeukemiaAMLChronic Myelogenous LeukemiaCMLMyeloproliferative NeoplasmNon Hodgkin LymphomaHodgkin LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaBurkitt LymphomaT-cell LymphomaB Cell LymphomaPeripheral T Cell LymphomaCutaneous B-Cell Lymphoma
Interventions
OTHER

1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.

Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER